Involvement of Cox-2 in the metastatic potential of chemotherapy-resistant breast cancer cells

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Kang, Ju Hee ^a,b   Song, Ki Hoon ^a   Jeong, Kyung Chae ^a   Kim, Sunshin ^a   Choi, Changsun ^b   Lee, Chang H ^c   Oh, Seung H ^a  

^a National Cancer Center   (South Korea)

^b Chung Ang University   (South Korea)

^c Dongguk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLOOXYGENASE 2; DOXORUBICIN; FIBRINOGEN; GELATIN; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 3; PROTEIN KINASE B; SMALL INTERFERING RNA; ANTINEOPLASTIC ANTIBIOTIC; EPIDERMAL GROWTH FACTOR RECEPTOR; PTGER1 PROTEIN, HUMAN; PTGER3 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CANCER RESISTANCE; CELL STRAIN MCF 7; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LUNG METASTASIS; MATRIX METALLOPEPTIDASE 9 GENE; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATOR UROKINASE GENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; GENETICS; LUNG TUMOR; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 79961125735     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-334     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001, 7(5):548-552. 10.1038/87872, 11329054.
3. Lukyanova NY, Rusetskya NV, Tregubova NA, Chekhun VF. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol 2009, 31(2):87-91.
4. Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009, 273(2):243-249. 10.1016/j.canlet.2008.08.015, 18804908.
5. Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005, 96(2):287-295. 10.1016/j.ygyno.2004.10.026, 15661210.
6. Luo D, Cheng SC, Xie H, Xie Y. Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem Cell Biol 2000, 78(2):119-126.
7. Cherbonnel-Lasserre C, Dosanjh MK. Suppression of apoptosis by overexpression of Bcl-2 or Bcl-xL promotes survival and mutagenesis after oxidative damage. Biochimie 1997, 79(9-10):613-617. 10.1016/S0300-9084(97)82011-1, 9466700.
8. Rudin CM, Thompson CB. Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 1997, 48:267-281. 10.1146/annurev.med.48.1.267, 9046961.
9. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18(55):7908-7916.
10. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996, 7(2):203-205. 10.1097/00001648-199603000-00017, 8834563.
11. Park K, Han S, Shin E, Kim HJ, Kim JY. Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 2006, 32(10):1093-1096. 10.1016/j.ejso.2006.05.010, 16797158.
12. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC, Tangrea JA. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?. Anticancer Res 2001, 21(3C):2141-2147.
13. Kurihara Y, Hatori M, Ando Y, Ito D, Toyoshima T, Tanaka M, Shintani S. Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis 2009, 26(5):425-432. 10.1007/s10585-009-9241-3, 19241124.
14. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005, 26(5):1393-1399.
15. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002, 62(3):632-635.
16. Kim EH, Na HK, Kim DH, Park SA, Kim HN, Song NY, Surh YJ. 15-Deoxy-Delta12,14-prostaglandin J2 induces COX-2 expression through Akt-driven AP-1 activation in human breast cancer cells: a potential role of ROS. Carcinogenesis 2008, 29(4):688-695.
17. Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer 2004, 90(3):712-719. 10.1038/sj.bjc.6601489, 2409599, 14760389.
18. Wang R, Wang X, Lin F, Gao P, Dong K, Zhang HZ. shRNA-targeted cyclooxygenase (COX)-2 inhibits proliferation, reduces invasion and enhances chemosensitivity in laryngeal carcinoma cells. Mol Cell Biochem 2008, 317(1-2):179-188. 10.1007/s11010-008-9847-9, 18592138.
19. Chan MW, Wong CY, Cheng AS, Chan VY, Chan KK, To KF, Chan FK, Sung JJ, Leung WK. Targeted inhibition of COX-2 expression by RNA interference suppresses tumor growth and potentiates chemosensitivity to cisplatin in human gastric cancer cells. Oncol Rep 2007, 18(6):1557-1562.
20. Zatelli MC, Mole D, Tagliati F, Minoia M, Ambrosio MR, degli Uberti E. Cyclo-oxygenase 2 modulates chemoresistance in breast cancer cells involving NF-kappaB. Cell Oncol 2009, 31(6):457-465.
21. Shtivelman E. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Oncogene 1997, 14(18):2167-2173. 10.1038/sj.onc.1201059, 9174052.
22. Takaoka A, Adachi M, Okuda H, Sato S, Yawata A, Hinoda Y, Takayama S, Reed JC, Imai K. Anti-cell death activity promotes pulmonary metastasis of melanoma cells. Oncogene 1997, 14(24):2971-2977. 10.1038/sj.onc.1201147, 9205104.
23. Chun KH, Lee HY, Hassan K, Khuri F, Hong WK, Lotan R. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 2003, 63(16):4796-4800.
24. Reimer CL, Agata N, Tammam JG, Bamberg M, Dickerson WM, Kamphaus GD, Rook SL, Milhollen M, Fram R, Kalluri R, Kufe D, Kharbanda S. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 2002, 62(3):789-795.
25. Oh SH, Lee OH, Schroeder CP, Oh YW, Ke S, Cha HJ, Park RW, Onn A, Herbst RS, Li C, Lee HY. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther 2006, 5(11):2685-2695. 10.1158/1535-7163.MCT-06-0142, 17121915.
26. Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes?. J Cell Biochem 1994, 56(1):37-47. 10.1002/jcb.240560108, 7806590.
27. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99(2):157-166. 10.1002/ijc.10329, 11979428.
28. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, Maggiano N, Gessi M, Mancuso S, Ranelletti FO, Scambia G. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002, 13(8):1205-1211. 10.1093/annonc/mdf207, 12181243.
29. Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 2002, 299(5):886-890. 10.1016/S0006-291X(02)02707-9, 12470662.
30. Simeone AM, Nieves-Alicea R, McMurtry VC, Colella S, Krahe R, Tari AM. Cyclooxygenase-2 uses the protein kinase C/interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells. Int J Oncol 2007, 30(4):785-792.
31. Xu K, Shu HK. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res 2007, 67(13):6121-6129. 10.1158/0008-5472.CAN-07-0141, 17616668.
32. Jiang Q, Zhou C, Bi Z, Wan Y. EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells. J Ocul Pharmacol Ther 2006, 22(2):93-102. 10.1089/jop.2006.22.93, 16722795.
33. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008, 13(1):16-24. 10.1634/theoncologist.2007-0199, 19001147.
34. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79(4):1193-1226.
35. Araki K, Hashimoto K, Ardyanto TD, Osaki M, Shomori K, Nakamura H, Ito H. Co-expression of Cox-2 and EGFR in stage I human bronchial adenocarcinomas. Lung Cancer 2004, 45(2):161-169. 10.1016/j.lungcan.2004.01.013, 15246187.
36. Ceccarelli C, Piazzi G, Paterini P, Pantaleo MA, Taffurelli M, Santini D, Martinelli GN, Biasco G. Concurrent EGFr and Cox-2 expression in colorectal cancer: proliferation impact and tumour spreading. Ann Oncol 2005, 16(Suppl 4):iv74-79.
37. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005, 23(2):254-266. 10.1200/JCO.2005.09.112, 15637389.
38. Kim HJ, Kim TY. IGF-II-mediated COX-2 gene expression in human keratinocytes through extracellular signal-regulated kinase pathway. J Invest Dermatol 2004, 123(3):547-555. 10.1111/j.0022-202X.2004.23317.x, 15304095.
39. St-Germain ME, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer 2004, 3:7. 10.1186/1476-4598-3-7, 394342, 15016316.
40. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, Acquaviva AM, Zarrilli R. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene 2000, 19(48):5517-5524. 10.1038/sj.onc.1203952, 11114729.